Clinical trial
A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell…
NCT02140554 · Genetix Biotherapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT02140554 |
|---|---|
| Title | A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease |
| Official title | A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease |
| Lead sponsor | Genetix Biotherapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Genetic |
| Interventions | lovo-cel |
| Enrollment | 54 |
| Start date | Feb 2, 2015 |
| Primary completion | Jul 31, 2023 |
| Completion | Jan 30, 2024 |
| First posted | May 16, 2014 |
| Last update posted | Mar 14, 2025 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: